ATLANTA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Ultragenyx’s expected results for its Phase III Orbit and Cosmic Studies, including setrusumab’s potential and the risks inherent in the study protocols put forth.
If you purchased Ultragenyx shares between August 3, 2023 and December 26, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/ultragenyx-pharmaceutical/ for more information.
The deadline to ask the court to be appointed lead plaintiff in the case is April 6, 2026.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
